New hope for stomach cancer: targeted drug BL-M07D1 enters final trial

NCT ID NCT07152405

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests a new drug called BL-M07D1 against standard chemotherapy in 490 people with HER2-positive advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. The study aims to see if BL-M07D1 helps people live longer or slows cancer growth. Participants will receive either BL-M07D1 or a doctor-chosen chemotherapy, given by infusion every few weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M07D1 (an antibody-drug conjugate targeting HER2)
What this could lead to: If successful, this could offer a new treatment option for people with HER2-positive advanced stomach cancer whose current therapy has stopped working.
What could go wrong: This is a phase 3 trial, but the drug is still experimental. It may not improve survival or could have side effects like other chemotherapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA GASTRIC OR GASTRO ESOPHAGEAL JUNCTION ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.